Stada Boosted By Consumer And Specialty Growth
As Generics Business Also Delivers Solid Improvement In 2022
Stada has celebrated “growing faster than the markets in which it operates” after delivering a 2022 performance that saw the firm’s earnings lifted in particular by increases in its consumer healthcare and specialty segments.
You may also be interested in...
Stada Begins Work On Romanian Hub
Stada has begun work on a facility in Romania into which the German giant is investing more than €50m to bolster the European supply chain.
Stada And Xbrane Gain EU All-Clear For Ranibizumab Biosimilar
The European Commission has approved Stada and Xbrane’s Ximluci ranibizumab biosimilar, the third Lucentis rival to be approved in the region so far. The companies are aiming to launch in early 2023 in selected European markets.
Stada’s Rare Kidney Disease Drug Is EU First
Stada advances its Specialty ambitions by launching the EU’s first authorized treatment for the rare kidney disease immunoglobulin A nephropathy in the form of its modified-release budesonide capsules.